SCHEMBL22976636

SCHEMBL22976636

Cc1cc(C)cc(-c2cncc(C(=O)O)c2N2CC[C@H](NC(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SSTR2 P30874 4/20 0.48
▸ KCNH2 Q12809 2/20 0.48
▸ SYK P43405 2/20 0.46
▸ CKS1B P61024 1/20 0.44
▸ SKP1 P63208 1/20 0.44
▸ SKP2 Q13309 1/20 0.44
▸ BTK Q06187 2/20 0.41
▸ SUV39H2 Q9H5I1 7/20 0.40
▸ CTSK P43235 2/20 0.40
▸ PDE10A Q9Y233 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ PIM3 Q86V86 1/20 0.39
▸ PIM2 Q9P1W9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720110 1.00 SSTR2 (0.48) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL22976638 1.00 SSTR2 (0.48) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL16694606 0.94 SSTR2 (0.52) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL29653565 0.89 SSTR2 (0.64) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL29653459 0.86 SYK (0.47) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL16694507 0.86 SSTR2 (0.52) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL16694809 0.84 SSTR2 (0.69) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL17965908 0.83 CKS1B (0.58) CKS1BSKP1SKP2BTKPIM1
SCHEMBL16694749 0.82 SSTR2 (0.50) SSTR2KCNH2SYKCKS1BSKP1
SCHEMBL16694607 0.80 SSTR2 (0.46) SSTR2KCNH2SYKCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2026-04-14 — — US disclosed
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2025-05-01 — — US disclosed
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2022-10-25 — — US disclosed
EP-4013748-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-06-22 — — EP disclosed
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-05-12 — — US disclosed
WO-2021030262-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-02-18 — — WO disclosed
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 SSTR2 4/4885KCNH2 3581/4885SYK 1500/4885
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, SSTR3 SSTR2 4/4885KCNH2 3581/4885SYK 1500/4885
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 SSTR2 4/4885KCNH2 3581/4885SYK 1500/4885
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 SSTR2 4/4885KCNH2 3581/4885SYK 1500/4885
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, GLP1R SSTR2 4/4885KCNH2 1162/4885SYK 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback